Skip to content

Thursday, November 21, 2024

Latest:

FROM THE LABS: From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide
The dangers of vaping
Thanksgiving nutrition: enjoying holiday favorites while staying on track with your health goals
How tau becomes a ‘bad guy’ that contributes to Alzheimer’s disease
Diabetes and depression: Is there a connection between them?

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

CAR T cell

A potential new therapeutic target for Group 3 medulloblastoma

August 8, 2024 CAR T cell, grade3-medulloblastoma, Immunotherapy, pediatric brain cancer, protogenin, Research

Researchers identified and located a population of stem-like cells that initiates and maintains Group 3 medulloblastoma in the developing brain.

New insights into the mediators of patient recovery after CAR T cell immunotherapy

July 21, 2020 cancer therapy, CAR T cell, Clinical Trials, complete response, HER-2, Immunotherapy, Research, rhabdomyosarcoma

Clinical trial of novel personalized CAR T cell immunotherapy provides clues into what mediated exceptional patient recovery.

From the Labs: Image of the Month

From the Labs: Aging signs.

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951